(9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate | 316152-95-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate
• 英文别名: N-benzyl-4-(N'-Boc-amino)-(S)-2-(N''-Fmoc-amino)butanamide；(S)-N-benzyl-4-(N'-Boc-amino)-2-(N''-Fmoc-amino)butyramide；tert-butyl N-[(3S)-4-(benzylamino)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxobutyl]carbamate
• CAS: 316152-95-1
• 化学式: C₃₁H₃₅N₃O₅
• 分子量: 529.636
• InChiKey: DUICJBVTYLAESJ-MHZLTWQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate 在 哌啶 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 1.5h， 生成 (S)-2-amino-4-(N-Boc-amino)-N'-benzylbutyramide
  参考文献：
  名称：

  [EN] SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS
  [FR] AGONISTES ET ANTAGONISTES SELECTIFS DU RECEPTEUR DE LA SOMATOSTATINE 1 ET/OU 4

  摘要：

  这项发明涉及基于(杂)芳基磺酰胺的肽类模拟物，其化学式为(I)，其中R1、R2、R3、A、B、D、Q、k和n的定义如所披露的，或其药学上可接受的盐或酯。化合物的化学式(I)具有对生长抑素受体亚型SSTR1和/或SSTR4的高亲和力和选择性，并可用于治疗或诊断需要与SSTR1和/或SSTR4相互作用的疾病或病况。

  公开号：

  WO2005033069A1
• 作为产物：
  描述：

  NAlpha-芴甲氧羰基-Nγ-羰-L-2,4-氨基丁酸 、 苄胺 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 乙腈 为溶剂， 反应 2.5h， 生成 (9H-fluoren-9-yl)methyl tert-butyl (4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-dicarbamate
  参考文献：
  名称：

  Novel indole peptidomimetics as thrombin receptor antagonists

  摘要：

  该发明涉及一种新型吲哌啶肽类模拟化合物，可用作治疗与血栓形成、再狭窄、高血压、心力衰竭、心律失常、炎症、心绞痛、中风、动脉粥样硬化、缺血情况、血管生成相关疾病、癌症和神经退行性疾病相关的疾病的凝血酶受体拮抗剂。还公开了包含本发明替代吲哌啶肽类模拟化合物的药物组合物以及治疗由凝血酶受体介导的疾病的方法。

  公开号：

  US20030224999A1

文献信息

• Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
  申请人：Tomperi Jussi

  公开号：US20100048549A1

  公开（公告）日：2010-02-25

  The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1, R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst 1 and/or sst 4 and can be used for the treatment or diagnosis of diseases or conditions wherein sst 1 and/or sst 4 agonists or antagonists are indicated to be useful.

  本发明涉及公式（I）中基于（杂）芳基磺酰氨基的肽类类似物，其中A，D，E，J，Q1，R1，R2，R3，p和j如所述定义，或其药学上可接受的盐或酯。公式（I）化合物具有对生长抑素受体亚型sst1和/或sst4的高亲和力和选择性，并可用于治疗或诊断sst1和/或sst4激动剂或拮抗剂被认为有用的疾病或情况。
• Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells
  作者：Disha M. Gandhi、Mark W. Majewski、Ricardo Rosas、Kaitlin Kentala、Trevor J. Foster、Eric Greve、Chris Dockendorff

  DOI：10.1016/j.bmc.2018.04.016

  日期：2018.5

  Several classes of ligands for Protease-Activated Receptors (PARs) have shown impressive anti-inflammatory and cytoprotective activities, including PAR2 antagonists and the PAR1-targeting parmodulins. In order to support medicinal chemistry studies with hundreds of compounds and to perform detailed mode-of-action studies, it became important to develop a reliable PAR assay that is operational with endothelial cells, which mediate the cytoprotective effects of interest. We report a detailed protocol for an intracellular calcium mobilization assay with adherent endothelial cells in multiwell plates that was used to study a number of known and new PAR1 and PAR2 ligands, including an alkynylated version of the PAR1 antagonist RWJ-58259 that is suitable for the preparation of tagged or conjugate compounds. Using the cell line EA. hy926, it was necessary to perform media exchanges with automated liquid handling equipment in order to obtain optimal and reproducible antagonist concentration-response curves. The assay is also suitable for study of PAR2 ligands; a peptide antagonist reported by Fairlie was synthesized and found to inhibit PAR2 in a manner consistent with reports using epithelial cells. The assay was used to confirm that vorapaxar acts as an irreversible antagonist of PAR1 in endothelium, and parmodulin 2 (ML161) and the related parmodulin RR-90 were found to inhibit PAR1 reversibly, in a manner consistent with negative allosteric modulation. (C) 2018 Elsevier Ltd. All rights reserved.
• Discovery and Optimization of a Novel Series of Thrombin Receptor (PAR-1) Antagonists:  Potent, Selective Peptide Mimetics Based on Indole and Indazole Templates
  作者：Han-Cheng Zhang、Claudia K. Derian、Patricia Andrade-Gordon、William J. Hoekstra、David F. McComsey、Kimberly B. White、Brenda L. Poulter、Michael F. Addo、Wai-Man Cheung、Bruce P. Damiano、Donna Oksenberg、Elwood E. Reynolds、Anjali Pandey、Robert M. Scarborough、Bruce E. Maryanoff

  DOI：10.1021/jm000506s

  日期：2001.3.1
• WO2006/123020
  申请人：——

  公开号：——

  公开（公告）日：——
• SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS
  申请人：Wurster, Siegfried

  公开号：EP1675824B1

  公开（公告）日：2010-09-29